跳至主要内容
临床试验/NCT05655065
NCT05655065
招募中
不适用

Effects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure : a Pilot Study for the Individualization of Mean Arterial Pressure

University Hospital, Angers3 个研究点 分布在 1 个国家目标入组 30 人2023年1月2日

概览

阶段
不适用
干预措施
increase of mean arterial pressure at 65-70 mmHg
疾病 / 适应症
Shock
发起方
University Hospital, Angers
入组人数
30
试验地点
3
主要终点
Changes of creatinine clearance
状态
招募中
最后更新
26天前

概览

简要总结

The purpose of this study is to assess the effect of a higher mean arterial pressure on renal function for patients with shock and elevated central venous pressure.

详细描述

Current recommandation for mean arterial pressure (MAP) target is 65 mmHg for septic shock, but optimal target to prevent acute renal failure (ARF) remains unknown. High central venous pressure (CVP) can lead to acute renal failure through venous congestion , and is associated with acute renal failure in intensive care unit. A decrease of renal perfusion pressure, defined by MAP - CVP, has been shown to be associated with risk of acute renal failure. The main objective of this trial is to evaluate if an optimisation of renal perfusion pressure, by a higher MAP when CVP is high (≥ 12 cmH2O), can improve renal function. In this interventional monocenter trial, each patient will be evaluated during 2 consecutive periods of 6 hours, with a temporary MAP target * Target at 65-70mmHg during 6 hours * Target at 80-85mmHg during 6 hours Patients will be randomized into two groups to define the order of targets. There will be a stratification on previous arterial hypertension. Renal function will be measured at the end of each period.

注册库
clinicaltrials.gov
开始日期
2023年1月2日
结束日期
2026年12月31日
最后更新
26天前
研究类型
Interventional
研究设计
Crossover
性别
All

研究者

发起方
University Hospital, Angers
责任方
Sponsor

入排标准

入选标准

  • Adult patients (≥ 18 years old )
  • Arterial hypotension requiring the etablishment of catecholamines
  • Norepinephrine dose ⩾ 0.1µg/kg/min at the inclusion
  • High central venous pressure ≥ 12mmHg
  • Cardiac output monitoring (PICCO or Swan Ganz)

排除标准

  • Patient with an emergency indication of renal replacement therapy (severe hyperkalemia, severe metabolical acidosis with pH \<7.15, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration \> 40 mmol/l)
  • Pregnant, lactating or parturient woman
  • Patient deprived of liberty by judicial or administrative decision
  • Patient with psychiatric compulsory care
  • Patient subject to legal protection measures
  • Patients with do-no-reanimate order or withdrawal of life sustaining support

研究组 & 干预措施

Increase of MAP at low target 65-70 mmHg (with catecholamines or volemic expansion)

Target of mean arterial pressure (MAP) at 65-70 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.

干预措施: increase of mean arterial pressure at 65-70 mmHg

Increase of MAP at high target 80-85 mmHg (with catecholamines or volemic expansion)

Target of mean arterial pressure (MAP) at 80-85 mmHg The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations.

干预措施: increase of mean arterial pressure at 80-85 mmHg

结局指标

主要结局

Changes of creatinine clearance

时间窗: At 6 hours and at 12 hours

Creatinine clearance is calculated with the formula UV/P as follow : * U being the urinary creatinine concentration in μmol/l * V the urinary volume expressed in ml per unit time * P the plasmatic creatinine concentration in μmol/l

次要结局

  • Arterial hypertension treatment(At inclusion.)
  • Introduction time of norepinephrine(At inclusion)
  • Norepinephrine dose(At inclusion, then every hours up to hour 12)
  • Number of days in intensive care unit(Day 90)
  • Survival at day 90(Day 90)
  • Co-morbidities(At inclusion.)
  • Intra-vesical pression(At inclusion then every hour up to 12 hours.)
  • Pulmonary compliance(At inclusion, at 6 hours and at 12 Hours.)
  • Changes of renal resistive index(At 6 hours and 12 hours)
  • Amount of fluids (unit = L )(At 6 hours and 12 hours)
  • Quantity of nephrotoxic drugs(At inclusion, at 6 hours and 12 hours)
  • Number of day with supportive care in intensive care unit (cathecolamines, renal replacement therapy, mechanical ventilation, extracorporeal membrane oxygenation)(Day 90)
  • Number of days in hospital(Day 90)
  • Tricuspid annular plane systolic excursion (TAPSE)(At inclusion, at 6 hours and at 12 hours.)
  • Plateau pressure(At inclusion, at 6 hours and at 12 Hours.)
  • End-expiratory pressure(At inclusion, at 6 hours and at 12 Hours.)
  • paCO2(At inclusion, at 6 hours and at 12 hours.)
  • Echocardiographic evaluation of left ventricular function(At inclusion, at 6 hours et at 12 hours)
  • Cardiac index measured(At inclusion and every hour up to 12 hours.)
  • Right S' wave(At inclusion, at 6 hours and at 12 hours.)
  • Tidal volume(At inclusion, at 6 Horus and at 12 jours)
  • Pulmonary pressions(At inclusion and every hour up to 12 hours)
  • Collection of all adverse event(At 6 hours and at 12 hours.)
  • paO2(At inclusion, at 6 hours and at 12 hours.)
  • Continuous cardiac output(At inclusion and every hour up to 12 hours)
  • Extra vascular lung water(At inclusion and every hour up to 12 hours)
  • Pulmonary Vascular Permeability Indice(At inclusion and every hour up to 12 hours)
  • Troponin(At inclusion, at 6 hours and at 12 hours.)
  • Ionogram(At inclusion, at 6 hours and at 12 hours.)
  • Lactates(At inclusion, at 6 hours and at 12 hours.)

研究点 (3)

Loading locations...

相似试验